Design and Synthesis of Pyrazoline Inhibitors of SARS-CoV‑2 NSP14

  • ACS Med Chem Lett. 2025 Sep 5;16(10):1918-1926. doi: 10.1021/acsmedchemlett.5c00155.
Elliott B Smyth  1  2 João P Pisco  1 Kristian Birchall  1 Nicole S Upfold  3 Arvind H Patel  3  4 Richard Foster  2 Jonathan M Large  1
Affiliations
  • 1. LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, U.K.
  • 2. School of Chemistry, University of Leeds, Leeds LS2 9JT, U.K.
  • 3. MRC-University of Glasgow Centre for Virus Research, Sir Michael Stoker Building, Garscube Campus, 464 Bearsden Road, Glasgow G61 1QH, U.K.
  • 4. CVR-CRUSH, MRC-University of Glasgow Centre for Virus Research, Sir Michael Stoker Building, Garscube Campus, 464 Bearsden Road, Glasgow G61 1QH, U.K.
Abstract

Non-structural protein 14 (NSP14) is a key two-domain protein responsible for maintaining coronavirus replication fidelity, and in its absence reproduction is severely impacted. With the goal of identifying new inhibitors of SARS-CoV-2 NSP14, we selected a previously reported scaffold as an appropriate starting point. Medicinal chemistry exploration provided a series of trisubstituted pyrazolines as inhibitors of NSP14 methyltransferase (MTase) activity, with improved synthetic tractability and in a promising molecular property space. This led to compound 35 as a potent inhibitor of NSP14 MTase with a favorable in vitro ADMET profile, and Antiviral activity against SARS-CoV-2 replication. We propose that 35 is a useful chemical probe which is well-positioned to further interrogate in vitro biology and for further optimization toward the treatment of human coronaviruses.

Keywords
Inhibition; Inhibitors; Ligands; Molecules; Peptides and Proteins; SARS-CoV-2.
Products